致幻剂治疗药物开发中的神经影像学:过去、现在与未来
致幻剂治疗(PT)在抑郁、成瘾、创伤后应激障碍等精神疾病中具有跨诊断潜力,经典血清素能致幻剂如裸盖菇素和LSD主要作用于5-HT2A受体。现代PT开发与神经影像学广泛应用同步,本文综述现有数据趋势,指出急性药物效应与长期临床效应关系、5-HT2A受体效应精确刻画及神经可塑性影响三个关键知识缺口,并提出以PET/MRI多模态研究为主的未来路线图。
要点
- 致幻剂治疗对抑郁、成瘾、PTSD等具有跨诊断潜力,经典血清素能致幻剂主要作用于5-HT2A受体。
- 神经影像学可更精确量化药物与治疗的大脑效应,现有数据表明PT开发极大受益于神经影像学。
- 未来需用PET/MRI多模态研究直接解决急性效应与长期临床效应关系等三个关键问题。
核心结论
- 致幻剂治疗的现代开发极大受益于神经影像学的使用,但急性药物效应与长期临床效应关系等关键知识缺口仍需未来研究解决。
研究设计与样本
- 本文为综述,梳理致幻剂治疗药物开发中神经影像学应用的现有数据趋势并提出未来研究路线图。
主要发现
- 经典血清素能致幻剂如裸盖菇素和LSD的关键作用位点为5-HT2A受体,氯胺酮、MDMA和伊博格碱也具前景。
- 现有知识的重要缺口包括急性药物效应与长期临床相关效应的关系、5-HT2A受体效应的精确刻画及其与功能/临床效应的关系、这些化合物对神经可塑性的可能影响。
关键数值与推荐
- 未来研究路线图主要采用正电子发射断层扫描(PET)与磁共振成像(MRI)联合方法及其他辅助技术。
- 多模态PET/MRI研究使用5-HT2A选择性配体[11C]Cimbi-36及其他对神经可塑性变化敏感的配体,结合MRI脑功能测量,可提供分子-功能-临床桥梁。
临床怎么用
- 临床开发中可利用神经影像学更精确量化致幻剂药物与治疗的大脑效应。
- 未来应优先开展直接针对急性效应与长期临床效应关系、5-HT2A受体效应刻画及神经可塑性影响的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), which have a key locus of action at the 5-HT2A receptor, form the main focus of this movement, but substances including ketamine, 3,4-Methylenedioxymethamphetamine (MDMA) and ibogaine also hold promise. The modern phase of development of these treatment modalities in the early 21st century has occurred concurrently with the wider use of advanced human neuroscientific research methods; principally neuroimaging. This can potentially enable assessment of drug and therapy brain effects with greater precision and quantification than any previous novel development in psychiatric pharmacology. We outline the major trends in existing data and suggest the modern development of PT has benefitted greatly from the use of neuroimaging. Important gaps in existing knowledge are identified, namely: the relationship between acute drug effects and longer-term (clinically-relevant) effects, the precise characterisation of effects at the 5-HT2A receptor and relationships with functional/clinical effects, and the possible impact of these compounds on neuroplasticity. A road-map for future research is laid out, outlining clinical studies which will directly address these three questions, principally using combined Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) methods, plus other adjunct techniques. Multimodal (PET/MRI) studies using modern PET techniques such as the 5-HT2A-selective ligand [11 C]Cimbi-36 (and other ligands sensitive to neuroplasticity changes) alongside MRI measures of brain function would provide a 'molecular-functional-clinical bridge' in understanding. Such results would help to resolve some of these questions and provide a firmer foundation for the ongoing development of PT.
引用
- Wall MB, Harding R, Zafar R, et al. Neuroimaging in psychedelic drug development: past, present, and future. Mol Psychiatry. 2023. PMID: 37759038. doi:10.1038/s41380-023-02271-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。